Company profile: CereVasc
1.1 - Company Overview
Company description
- Provider of endovascular medical devices for treating hydrocephalus, including the eShunt System—an endovascularly implantable cerebrospinal fluid shunt with delivery components designed to treat communicating hydrocephalus without invasive surgery—and a portfolio of follow-on product concepts to improve care for neurovascular diseases, including therapies deliverable across the blood-brain barrier.
Products and services
- Associated Delivery Components: Engineers associated endovascular delivery components that implant the eShunt without invasive surgery, enabling treatment of communicating hydrocephalus with minimally disruptive access
- EShunt System: Builds an endovascularly implantable cerebrospinal fluid (CSF) shunt and associated delivery components designed to treat communicating hydrocephalus without invasive surgery
- Follow-On Products: Develops follow-on product concepts aimed at improving care for neurovascular diseases, featuring therapies that can be delivered across the blood-brain barrier.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CereVasc
Orexo
HQ: Sweden
Website
- Description: Provider of pharmaceutical treatments and drug delivery technologies, including Zubsolv, a medication for opioid dependence commercialized in the US, and AmorphOX, a proprietary nasal delivery technology used to develop new pharmaceutical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orexo company profile →
Predix Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug discovery and development leveraging a novel 3D Discovery and Optimization Engine for GPCR drug candidates. Utilizes the proprietary PREDICT algorithm to computer-model the 3D structure of any GPCR target and advance novel compounds into the clinic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predix Pharmaceuticals company profile →
Landos Biopharma
HQ: United States
Website
- Description: Provider of oral, first-in-class, locally acting small-molecule therapeutics for autoimmune diseases. Pipeline: NX-13 (NLRX1) for ulcerative colitis and Crohn’s; LABP-66 (NLRX1) for multiple sclerosis and neurodegenerative disorders; LABP-73 (NLRX1) for asthma and eosinophilic disorders; LABP-69 (PLXDC2) for rheumatoid arthritis, ulcerative colitis, and Crohn’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Landos Biopharma company profile →
Oculogica
HQ: United States
Website
- Description: Provider of neuro-diagnostic medical devices and training focused on TBI, concussion, and eye-tracking. Products include EyeBOX, an FDA-cleared, baseline-free, non-invasive device that tracks eye movements to aid in concussion (mTBI) diagnosis with results in under four minutes, and OcuPro, a roadside test for law enforcement to detect recent cannabis use and impairment. Offers EyeBOX training to customers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oculogica company profile →
MAP Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel inhalation therapies under development for respiratory and systemic diseases, with proprietary product candidates including Unit Dose Budesonide for pediatric asthma (children six months to eight years) and MAP0004 for migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAP Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CereVasc
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CereVasc
2.2 - Growth funds investing in similar companies to CereVasc
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CereVasc
4.2 - Public trading comparable groups for CereVasc
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →